Sökning: onr:"swepub:oai:DiVA.org:oru-94785" >
The Cost-Effectiven...
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes : a Health Economic Analysis in Sweden
-
- Jendle, Johan, 1963- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
- Buompensiere, M. I. (författare)
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland
-
- Holm, A. L. (författare)
- Medtronic Denmark, Copenhagen, Denmark
-
visa fler...
-
- de Portu, S. (författare)
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland
-
- Malkin, S. J. P. (författare)
- Ossian Health Economics and Communications, Basel, Switzerland
-
- Cohen, O. (författare)
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland
-
visa färre...
-
(creator_code:org_t)
- 2021-10-01
- 2021
- Engelska.
-
Ingår i: Diabetes Therapy. - : Springer. - 1869-6953 .- 1869-6961. ; 12:11, s. 2977-2991
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION: Swedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.METHODS: Outcomes were projected over patients' lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.RESULTS: The MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained.CONCLUSIONS: Based on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Advanced hybrid closed-loop
- Cost-effectiveness
- Sweden
- Type 1 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas